ATE265224T1 - Glp-1 derivate mit einem helix-gehalt über 25 , die partiell strukturierte mizellenartige aggregate bilden - Google Patents

Glp-1 derivate mit einem helix-gehalt über 25 , die partiell strukturierte mizellenartige aggregate bilden

Info

Publication number
ATE265224T1
ATE265224T1 AT99906077T AT99906077T ATE265224T1 AT E265224 T1 ATE265224 T1 AT E265224T1 AT 99906077 T AT99906077 T AT 99906077T AT 99906077 T AT99906077 T AT 99906077T AT E265224 T1 ATE265224 T1 AT E265224T1
Authority
AT
Austria
Prior art keywords
glp
aggregates
derivatives
content over
partially structured
Prior art date
Application number
AT99906077T
Other languages
English (en)
Inventor
Liselotte Bjerre Knudsen
Per Olaf Huusfeldt
Per Franklin Nielsen
Niels C Kaarsholm
Helle Birk Olsen
Soren Erik Bjorn
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Application granted granted Critical
Publication of ATE265224T1 publication Critical patent/ATE265224T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
AT99906077T 1998-02-27 1999-02-25 Glp-1 derivate mit einem helix-gehalt über 25 , die partiell strukturierte mizellenartige aggregate bilden ATE265224T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DK26898 1998-02-27
DK27298 1998-02-27
PCT/DK1999/000084 WO1999043341A1 (en) 1998-02-27 1999-02-25 Glp-1 derivatives with helix-content exceeding 25 %, forming partially structured micellar-like aggregates

Publications (1)

Publication Number Publication Date
ATE265224T1 true ATE265224T1 (de) 2004-05-15

Family

ID=26063652

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99906077T ATE265224T1 (de) 1998-02-27 1999-02-25 Glp-1 derivate mit einem helix-gehalt über 25 , die partiell strukturierte mizellenartige aggregate bilden

Country Status (6)

Country Link
EP (1) EP1061946B1 (de)
JP (1) JP2002504518A (de)
AT (1) ATE265224T1 (de)
AU (1) AU2610799A (de)
DE (1) DE69916811T2 (de)
WO (1) WO1999043341A1 (de)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69740096D1 (de) 1996-08-08 2011-02-17 Amylin Pharmaceuticals Inc Pharmazeutische Zusammensetzung mit einem Exendin-4-Peptid
JP2003519664A (ja) * 2000-01-11 2003-06-24 ノボ ノルディスク アクティーゼルスカブ Ｇｌｐ−１誘導体の経上皮送達
ES2253353T3 (es) 2000-03-08 2006-06-01 Novo Nordisk A/S Reduccion del colesterol serico.
PL206302B1 (pl) 2000-06-16 2010-07-30 Elli Lilly And Companyelli Lilly And Company Związek GLP-1
DE60136958D1 (de) 2000-12-01 2009-01-22 Takeda Pharmaceutical Verfahren zur herstellung einer zubereitung mit einer bioaktiven substanz
AU2002226897B2 (en) * 2000-12-07 2007-10-25 Eli Lilly And Company GLP-1 fusion proteins
DE60224284T2 (de) * 2001-06-28 2008-12-18 Novo Nordisk A/S Stabile formulierung von modifiziertem glp-1
CN1363654A (zh) * 2001-07-19 2002-08-14 上海华谊生物技术有限公司 生产促胰岛素分泌肽glp－1(7－36)的基因工程菌以及生产glp－1(7－36)的方法
AU2002322403A1 (en) 2001-08-23 2003-03-10 Eli Lilly And Company Glucagon-like peptide-1 analogs
KR101198346B1 (ko) 2003-04-08 2012-11-06 노보 노르디스크 에이/에스 크로마토그래피 고정상의 재생
WO2004089985A1 (en) 2003-04-11 2004-10-21 Novo Nordisk A/S Stable pharmaceutical compositions
BRPI0410972C1 (pt) 2003-06-03 2021-05-25 Novo Nordisk As método para aumentar a vida de armazenagem de uma composição farmacêutica, composição farmacêutica, e, método para tratamento de hiperglicemia
WO2004105790A1 (en) 2003-06-03 2004-12-09 Novo Nordisk A/S Stabilized pharmaceutical peptide compositions
TW200522976A (en) * 2003-09-19 2005-07-16 Novo Nordisk As Novel plasma protein affinity tags
SI2932981T1 (sl) * 2003-09-19 2021-11-30 Novo Nordisk A/S Albumin-vezavni derivati GLP-1
RU2421238C2 (ru) 2003-11-20 2011-06-20 Ново Нордиск А/С Пептидная композиция, содержащая пропиленгликоль, являющаяся оптимальной для изготовления и применения в инъекционных устройствах
ATE498404T1 (de) 2003-12-09 2011-03-15 Novo Nordisk As Regulierung der nahrungspräferenz mit glp-1- agonisten
TWI353250B (en) 2003-12-16 2011-12-01 Ipsen Pharma Sas Glp-1 pharmaceutical compositions
WO2005120492A1 (en) 2004-06-11 2005-12-22 Novo Nordisk A/S Counteracting drug-induced obesity using glp-1 agonists
EP1789434B1 (de) 2004-08-31 2013-11-20 Novo Nordisk A/S Verwendung von tris(hydroxymethyl)-aminomethan zur stabilisierung von peptiden, polypeptiden und proteinen
JP5107713B2 (ja) 2004-10-07 2012-12-26 ノヴォ ノルディスク アー／エス 遅延性のエキセンディン−４化合物
US7893017B2 (en) 2004-10-07 2011-02-22 Novo Nordisk A/S Protracted GLP-1 compounds
PL1817048T3 (pl) 2004-11-12 2014-07-31 Novo Nordisk As Stabilne preparaty peptydów insulinotropowych
TWI362392B (en) 2005-03-18 2012-04-21 Novo Nordisk As Acylated glp-1 compounds
CA2596926A1 (en) 2005-03-18 2006-09-21 Novo Nordisk A/S Extended glp-1 compounds
JP5977945B2 (ja) 2008-08-06 2016-08-24 ノヴォ・ノルディスク・ヘルス・ケア・アーゲー 長期のインビボ有効性を有するコンジュゲートタンパク質
MX2011007736A (es) 2009-01-22 2011-09-06 Novo Nordisk Healthcare Ag Compuestos de hormona del crecimiento estables.
CN102612376A (zh) 2009-08-06 2012-07-25 诺沃-诺迪斯克保健股份有限公司 具有延长的体内功效的生长激素
WO2011089255A1 (en) 2010-01-22 2011-07-28 Novo Nordisk Health Care Ag Growth hormones with prolonged in-vivo efficacy
EP2525833A2 (de) 2010-01-22 2012-11-28 Novo Nordisk Health Care AG Stabile wachstumshormonverbindungen
US9168288B2 (en) 2010-04-09 2015-10-27 Mount Sinai Hospital Methods for treating disorders of the gastrointestinal tract using a GLP-1 agonist
US20130123460A1 (en) 2010-04-30 2013-05-16 Sanwa Kagaku Kenkyusho Co., Ltd. Peptide for improving biostability of bioactive substance, and bioactive substance having improved biostability
SI2651398T1 (en) 2010-12-16 2018-04-30 Novo Nordisk A/S SOLID COMPOSITIONS CONTAINING GLP-1 AGONIST AND SOL N- (8- (2-HYDROXYBENZOIL) AMINO) CAPRICULATE ACIDS
US10335369B2 (en) 2012-03-22 2019-07-02 Novo Nordisk A/S Compositions comprising a delivery agent and preparation thereof
RS57727B1 (sr) 2012-03-22 2018-12-31 Novo Nordisk As Kompozicije glp-1 peptida i njihovo dobijanje
WO2014010586A1 (ja) 2012-07-10 2014-01-16 武田薬品工業株式会社 注射用製剤
EP2908844A1 (de) 2012-10-17 2015-08-26 Novo Nordisk A/S Fettsäureacylierte aminosäuren zur oralen peptidfreisetzung
EP2981282B1 (de) 2013-04-05 2020-11-04 Novo Nordisk Health Care AG Wachstumshormonverbindungsformulierung
DK3006045T3 (en) 2014-10-07 2017-07-17 Cyprumed Gmbh Pharmaceutical formulations for oral administration of peptide or protein drugs
EP3359181A1 (de) 2015-10-07 2018-08-15 Cyprumed GmbH Pharmazeutische formulierungen zur oralen verabreichung von peptidarzneimitteln
WO2018065634A1 (en) 2016-10-07 2018-04-12 Cyprumed Gmbh Pharmaceutical compositions for the nasal delivery of peptide or protein drugs
TWI783890B (zh) 2017-08-24 2022-11-11 丹麥商諾佛 儂迪克股份有限公司 Glp-1組成物及其用途
AR114353A1 (es) 2018-02-02 2020-08-26 Novo Nordisk As Composiciones sólidas que comprenden un agonista del glp-1 y una sal del ácido n-(8-(2-hidroxibenzoil)amino)caprílico
JP7442823B2 (ja) 2018-04-06 2024-03-05 シプルメット・ゲーエムベーハー 治療用ペプチド及び治療用タンパク質の経粘膜送達のための薬学的組成物
TWI829687B (zh) 2018-05-07 2024-01-21 丹麥商諾佛 儂迪克股份有限公司 包含glp-1促效劑與n-(8-(2-羥基苯甲醯基)胺基)辛酸之鹽的固體組成物
JP2022516439A (ja) 2018-12-21 2022-02-28 ジエンス ヘンルイ メデイシンカンパニー リミテッド 二特異性タンパク質
AU2021208601A1 (en) 2020-02-18 2022-07-28 Novo Nordisk A/S Glp-1 compositions and uses thereof
CN115461044A (zh) 2020-04-29 2022-12-09 诺和诺德股份有限公司 包含glp-1激动剂和组氨酸的固体组合物
US20240041983A1 (en) 2020-09-07 2024-02-08 Cyprumed Gmbh Improved pharmaceutical formulations of glp-1 receptor agonists
JP2023545684A (ja) 2020-09-30 2023-10-31 ベイジン キューエル バイオファーマシューティカル カンパニー，リミテッド ポリペプチドコンジュゲートおよび使用の方法
WO2023012263A1 (en) 2021-08-04 2023-02-09 Novo Nordisk A/S Solid oral peptide formulations
CN116730902B (zh) * 2023-08-07 2023-11-21 杭州湃肽生化科技有限公司 一种合成利拉鲁肽的方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5614492A (en) * 1986-05-05 1997-03-25 The General Hospital Corporation Insulinotropic hormone GLP-1 (7-36) and uses thereof
EP1498425A1 (de) * 1986-05-05 2005-01-19 The General Hospital Corporation Verwendung von Glucagonähnlichem-Peptid-1 (GLP-1) Derivaten zur Herstellung von pharmazeutischen Zusammensetzungen
ATE193541T1 (de) * 1989-03-20 2000-06-15 Gen Hospital Corp Insulinotropes hormon
ES2113879T3 (es) * 1990-01-24 1998-05-16 Douglas I Buckley Analogos de glp-1 utiles para el tratamiento de diabetes.
ES2283025T3 (es) * 1996-08-30 2007-10-16 Novo Nordisk A/S Derivados de glp-1.1.

Also Published As

Publication number Publication date
WO1999043341A1 (en) 1999-09-02
DE69916811T2 (de) 2005-04-14
EP1061946A1 (de) 2000-12-27
DE69916811D1 (de) 2004-06-03
EP1061946B1 (de) 2004-04-28
JP2002504518A (ja) 2002-02-12
AU2610799A (en) 1999-09-15

Similar Documents

Publication Publication Date Title
ATE265224T1 (de) Glp-1 derivate mit einem helix-gehalt über 25 , die partiell strukturierte mizellenartige aggregate bilden
WO1999043361A8 (en) Glp-2 derivatives with helix-content exceeding 25 %, forming partially structured micellar-like aggregates
EE03423B1 (et) Kopolümeer-1, selle valmistamismeetod ja seda sisaldavad kompositsioonid
BR0212968A (pt) Composição farmacêutica, composto, e, método para tratar ou prevenir condições mediadas pelo ccr2, mcp-1 ou pela interação destes
LU91758I2 (fr) Denosumab et ses dérivés pharmaceutiquement acceptables (PROLIA®)
HUP9900936A1 (hu) Izocianátalapú készítmények, bevonatként történő alkalmazásuk és az így előállított bevonatok
WO2003037271A3 (en) Compounds, pharmaceutical compositions and methods of use therefor
HK1058934A1 (en) Cyclopentanoindoles, compositions containing such compounds and methods of treatment
DE60326435D1 (de) Rauchartikel mit verminderter entzündungstendenz
TR200101335T2 (tr) İktidarsızlık tedavisi için pirazolopirimidinon türevleri
MXPA05002442A (es) Imidazolopiridinas y metodos para la elaboracion y uso de las mismas.
MY130580A (en) Oxalylamino-benzofuran and benzothienyl derivatives
EP1203793A4 (de) Asphatlmodifizierungsmittel, verfahren zur herstellung von modifiziertem asphalt und verfahren zur herstellung eines strassenbelagmeterials
MY127953A (en) Gabapentin-containing solid compositions and process for preparing the same
EE9800022A (et) Karbapeneemühend, selle stabiliseerimismeetod ja stabiliseeritud vorm ning farmatseutiline kompositsioon
ATE229340T1 (de) Relaxinartiger faktor und damit zusammenhängende verfahren und verwendungen
ES2178209T3 (es) Procedimiento para preparar una composicion de asfalto.
ATE229518T1 (de) Cis-3,4-chromanderivate zur vorbeugung oder behandlungvon oestrogenbezogenen krankheiten oder syndromen
MXPA03002440A (es) Procedimiento de preparacion de pasta dentifrica empleando un jarabe de sorbitol particular, y jarabe de sorbitol.
HUT39601A (en) Process for producing synergistic contraceptive compositions
WO2002020661A8 (en) Paving and sealing composition and method of use
MY135972A (en) Egg anti-inflammatory composition and method of treating and preventing inflammation
BR0013266A (pt) Composição, utilização de uma composição e artigo acabado
BR9900024A (pt) Biciclo[3.1.0]hexanos e compostos relacionados.
AUPM519994A0 (en) Method of stabilising clay based soil aggregate mixtures, structures formed by the method and compositions for use in the method

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties